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ttp://dx.doi.org/10.1016/j.jmoldx.2014.05.006Amplicon-based methods for targeted resequencing of cancer genes have gained traction in the clinic as
a strategy for molecular diagnostic testing. An 847-amplicon panel was designed with the RainDance
DeepSeq system, covering most exons of 28 genes relevant to acute myeloid leukemia and myelopro-
liferative neoplasms. We developed a paired-sample analysis pipeline for variant calling and sought to
assess its sensitivity and speciﬁcity relative to a set of samples with previously identiﬁed mutations.
Thirty samples with known mutations in JAK2, NPM1, DNMT3A, MPL, IDH1, IDH2, CEBPA, and FLT3, were
proﬁled and sequenced to high depth. Variant calling using an unmatched Hapmap DNA control
removed a substantial number of artifactual calls regardless of algorithm used or variant class. The
removed calls were nonunique, had lower variant frequencies, and tended to recur in multiple unrelated
samples. Analysis of sample replicates revealed that reproducible calls had distinctly higher variant
allele depths and frequencies compared to nonreproducible calls. On the basis of these differences,
ﬁlters on variant frequency were chosen to select for reproducible calls. The analysis pipeline suc-
cessfully retrieved the associated known variant in all tested samples and uncovered additional mu-
tations in some samples corresponding to well-characterized hotspot mutations in acute myeloid
leukemia. We have developed a paired-sample analysis pipeline capable of robust identiﬁcation of
mutations from microdroplet-PCR sequencing data with high sensitivity and speciﬁcity. (J Mol Diagn
2014, 16: 504e518; http://dx.doi.org/10.1016/j.jmoldx.2014.05.006)Supported by the Department of Pathology, Memorial Sloan-Kettering
Cancer Center.
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Disclosures: None declared.Next-generation sequencing (NGS) technologies have trans-
formed the approach to the molecular diagnosis of cancer.1,2
After methodologic improvements in sequencing chemistry
and samplemultiplexing, NGS has rapidly decreased in cost in
recent years, allowing targeted resequencing of cancer-related
genes3,4 or mutational hotspots5 to become viable options as
routine clinical diagnostic assays. An increasing number of
medical research institutes and health care providers have
developed NGS assays for clinical applications to provide
targeted therapy in prospective use6 and to identify genetic
alterations associated with a speciﬁc phenotype in retrospec-
tive analysis.7 Amplicon-based approaches have emerged as a
popular strategy for target resequencing, and several com-
mercial platforms are currently available (eg, Illumina TruSeqstigative Pathology
.Custom Amplicon and Ion Torrent Ampliseq). The Rain-
Dance DeepSeq system is an example of an amplicon-based
platform that is differentiated by its use of microdroplet-
PCR, which allows for the simultaneous ampliﬁcation of a
large number of targeted regions without disruptions due to
primer pair interactions.8 In this study, we sought to leverage
the advantages of microdroplet-PCR in the development of an
amplicon panel designed to interrogate mutations across 353
exons of 28 genes known to be involved in the pathogenesis of
myeloid malignancies.
Deep Sequencing of Microdroplet PCRMyeloid neoplasms are characterized by a number of
recurrent somatic mutations in genes regulating growth and
differentiation9 that have been identiﬁed by gene expression
proﬁling,10 epigenetic proﬁling,11 and more recently NGS.12
Mutations in genes such as JAK213 and MPL14,15 have diag-
nostic utility in the classiﬁcation of myeloproliferative neo-
plasms (MPNs), and recurrent mutations in FLT3, NPM1,
IDH1, IDH2, DNMT3A, KIT, and CEBPA found in cytoge-
netically normal acute myeloid leukemia (AML) have been
found to have prognostic signiﬁcance in a variety of clinical
settings, such as determining whether a patient is likely to
beneﬁt from an allogeneic bone marrow transplantation, a
procedure with a signiﬁcant morbidity and mortality rate.16,17
The types of mutations found in these genes vary from single-
nucleotide substitutions in IDH1 and IDH2 genes,18 small
insertions and deletions (indels) in the CEBPA19,20 and NPM1
genes,21 to larger duplications in the FLT3 gene.22 The variety
of mutation types involved, as well as the high likelihood of
mutations to occur in combination, presents a challenge for the
development of an NGS assay and a companion data analysis
pipeline capable of detecting mutations with high sensitivity
and speciﬁcity (low false discovery rate).
Unlike ready-made solutions, such as the Illumina TruSeq
Amplicon Cancer Panel and the Ion Torrent Ampliseq Cancer
Hotspot panel, the RainDance DeepSeq system does not come
with a vendor-supplied analysis pipeline. An in-house custom
analysis pipeline had to be developed to call variants from the
RainDance sequencing output, and in this study we detail the
assessment of various variant-calling algorithms that were
evaluated. Because most variant-calling algorithms were
developed for analysis of other sequencing data (whole genome
and whole exome), we also describe modiﬁcations in our pipe-
line to account for speciﬁc performance characteristics of
amplicon data (ie, bidirectional coverage due to amplicon tiling
and stereotypic start and stop sites for read pairs). We compare
differences in variants called in single-sample analysis (tumor
samples considered alone) versus paired-sample analysis (tumor
samples compared against a Hapmap DNA sample, used as a
generic unmatched normal control). We evaluate the perfor-
mance of the analysis pipeline, in terms of sensitivity and
reproducibility, on a validation set of 30 AML orMPN samples
with known mutations previously identiﬁed using independent
methods. Themain objective of this study is to provide proof-of-
concept that an NGS assay based on microdroplet-PCR is a
viableoptionasamoleculardiagnostic test in theclinic.Theneed
for a high-throughput approach for the genomic characterization
of AML or MPN is especially pertinent, given the increasing
numberof clinically relevantgenetic alterations inAMLorMPN
and others with possible targets for future clinical trials.
Materials and Methods
Patient Samples
Thirty bone marrow samples from patients with a clinical
diagnosis of AML or MPN with known mutations in JAK2,The Journal of Molecular Diagnostics - jmd.amjpathol.orgNPM1, FLT3, MPL, DNMT3A, IDH1, and IDH2 were sub-
jected to microdroplet-PCR followed by deep sequencing on
an Illumina MiSeq (Supplemental Tables S1 and S2). Known
mutations in these samples had been previously identiﬁed
using Sanger sequencing, fragment analysis (NPM1 or
FLT3), or restriction fragment length polymorphism assay
(JAK2). Ten samples were assayed in triplicate or greater, for
a total of 66 replicates. Nine samples positive for the NPM1
exon 11 insertion had a co-occurring internal tandem dupli-
cation (ITD) mutation in the FLT3 gene [identiﬁed by PCR
with primers directed at exons 14, 15, and 20, followed by
capillary gel electrophoresis to separate PCR products and
detection by ﬂuorescence (ARUP Laboratories, Salt Lake
City, UT)]. Five samples positive for JAK2 V617F and ﬁve
samples positive for the NPM1 exon 11 insertion were
repeated at least three times within and across runs to assess
intrarun and interrun reproducibility.
PCR and Sanger Sequencing
PCR was performed using JumpStart REDTaq ReadyMix
PCR Reaction Mix (Sigma-Aldrich, St. Louis, MO)
following vendor protocol. Sanger sequencing was per-
formed on PCR products using an ABI3730 instrument
(Life Technologies, Carlsbad, CA).
Microdroplet-PCR and Sequencing
Each pool consisted of 10 tumor samples, one control
sample containing DNA from a Hapmap cell line
(NA20810) and one no-template control. All samples in the
pool were subjected to microdroplet PCR, followed by
sequencing on an Illumina MiSeq and data analysis. Indi-
vidual steps in this workﬂow are described below.
GenomicDNAextraction fromblood andbonemarrowwas
performed using the Qiagen DNAeasy blood kit (Qiagen,
Venlo, the Netherlands) and quantiﬁed by a Qubit dsDNA
Broad Range Assay kit (Life Technologies). DNA shearing
was performed using 500 ng of DNA in Covaris Clear Mini
Tubes on anE-series DNASonicator (Covaris,Woburn,MA).
Fragmented DNA was subsequently puriﬁed using Qiagen
MinElute Clean-up (Qiagen) and subjected to RainDance
Thunderstorm instrument preparation (RainDance Technolo-
gies, Billerica, MA) following a vendor-speciﬁed protocol
where genomic DNA Template Mix and custom Primer Li-
brary weremerged to form the PCR droplets for ampliﬁcation.
After successful Thunderstorm merge, RainDance emul-
sion PCR (RainDance Technologies) was performed using
RainDance Droplet Stabilizer and Platinum High Fidelity
Taq (Life Technologies; following vendor protocol). Illu-
mina adaptor tails are added to the 50 end of the sequence
speciﬁc region of amplicon primers used in emulsion PCR
to allow for secondary PCR. The PCR droplet emulsion was
broken, and ampliﬁed PCR products were recovered using
RainDance Droplet Destabilizer (RainDance Technologies)
in combination with Qiagen MinElute Clean-up. Ampliﬁed505
Cheng et alPCR libraries were quantiﬁed on an Agilent Bioanalyzer
System (Agilent Technologies, Santa Clara, CA) to calcu-
late 10 ng of ampliﬁed PCR library per sample for sec-
ondary PCR. Secondary PCR was performed according to
vendor protocol in combination with custom-designed
reverse PCR primers from Integrated DNA Technologies
(Coralville, IA) containing unique barcodes. The forward
primer in secondary PCR is a universal primer, whereas the
reverse primer contains unique Illumina Truseq barcodes.
Secondary ampliﬁed PCR products were recovered using
Qiagen MinElute Clean-up and quantiﬁed using Agilent
Bioanalyzer System to calculate 15 ng of secondary
ampliﬁed PCR library per sample for library pooling.
The resulting pool was quantiﬁed by a Qubit dsDNA
Broad Range Assay kit and diluted for loading into a MiSeq
300 cycle reagent kit (Illumina, San Diego, CA) for
sequencing. RainDance Custom Sequencing Primers from
Integrated DNA Technologies were also loaded into the
MiSeq Reagent Cartridge for forward read and turnaround
read for 150 bp paired-end sequencing. Sequencing was
performed on Illumina MiSeq v.2 instrument (Illumina)
using an Illumina MiSeq Library QC sequencing workﬂow.
Statistical Analysis
CASAVA version 1.8.2 (Illumina) was used for sample
demultiplexing and FASTQ generation. An option within
CASAVA was enabled to mask adapter sequences in the
sequencing output. Reads were aligned to the genome (hg19)
using the Burrows-Wheeler Aligner.23 Aligned reads were
subjected to local indel realignment and base quality recali-
bration using the Genome Analysis Toolkit version 2.2.8
(https://www.broadinstitute.org/gatk).24 Variant calling was
performed on the recalibrated alignment output in single- and
paired-sample analyses using the following tools. For point
mutations and single nucleotide variants (SNVs),MuTect25 and
VarScan226,27 were used. For indels, SomaticIndelDetector24
and VarScan2 were used. Pindel28 was used for detection of
ITD events. In single-sample analysis, the algorithms listed
above were run in unpaired mode on the tumor sample only. In
paired-sample analysis, the algorithms were run in paired or
somaticmode on the tumor sample with the Hapmap sample
as a normal control (except for Pindel, which operates in
single-sample mode only, paired-sample analysis was
performed by removing calls made on the Hapmap normal
from the tumor calls.)
Variant calling was performed on the subset of targeted
regions where amplicon coverage was bidirectional. To
compare calls from multiple tools on a common standard, raw
SNV and indel calls from all algorithms were ﬁltered for
minimum base quality score of 20, minimum coverage of
100, and minimum variant frequency of 1%. We further
required all variant calls to be present on at least 4 reads in each
direction to avoidpotential strandbias artifacts.Annovar29was
used to annotate variants for changes on the cDNA and amino
acid level; variant calls were also checked against external506databases [ie, Catalogue of Somatic Mutations in Cancer
(COSMIC) version 64,30 Single Nucleotide Polymorphism
database version 137, and 1000 Genomes31] to determine
whether they corresponded to existing entries. Nonexonic
variants and silent, synonymous mutations were ﬁltered out;
coding variants corresponding to missense, nonsense muta-
tions, splice-sitemutations, frameshift, or in-frame indels were
kept. Because variant calling was performed in single-sample
mode or relative to an unmatched normal control, variants with
minor allele frequency>1% in the 1000Genomes cohort were
removed because they were likely common polymorphisms.
Statistical analysis was performed using R software version
2.15.2 (http://www.r-project.org).
Command line arguments for the tools mentioned are
included below:
1) Samtools
./samtools-0.1.19/samtools mpileup -A -B -C
0 -l <amplicon bed file> -f <hg19 genome refer-
ence fasta> -Q 20 -d 50000 <tumor bam file>
2) Varscan2: single-sample mode
java -Xmx4g -jar VarScan.v2.3.5.jar mpi-
leup2cns <tumor.mpileup> --min-coverage 100
--min-var-freq 0.01
3) Varscan2: paired-sample mode
java -Xmx4g -jar VarScan.v2.3.5.jar somatic
<normal.pileup> <tumor.pileup> <output.
somatic> --min-coverage 100 --min-var-
freq 0.01
4) MuTect: single-sample mode
java -Xmx4g -jar muTect-1.1.4.jar -T MuTect
--intervals <amplicon interval list file>
--input_file:tumor <Tumor bam file> --reference_
sequence <hg19 genome reference fasta> --dbsnp
dbsnp_137.vcf -o <mutect output file> --enable_
extended_output -dcov 50,000 -rf BadCigar
5) MuTect: paired-sample mode
java -Xmx4g -jar muTect-1.1.4.jar -T MuTect
--intervals <amplicon interval list file>
--input_file:normal <Hapmap bam file>
--input_file:tumor <Tumor bam file> --ref-
erence_sequence <hg19 genome reference fasta>
--dbsnp dbsnp_137.vcf -o <mutect output file>
--enable_extended_output -dcov 50,000 -rf
BadCigar
6) SomaticIndelDetector: single-sample mode
java -Xmx4g -jar GenomeAnalysisTK-2.2-8/
GenomeAnalysisTK.jar -T SomaticIndelDetector
--maxNumberOfReads 100000 -I:tumor <Tumor bam
file> --unpaired -filter y’T_COV<10jjT_INDEL_
F<0.0001jjT_INDEL_CF<0.7y’ -verbose <verbose
output> -o <standard output> -metrics <metrics
file> -R <hg19 genome reference fasta> -Ljmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 A: Distribution of mean coverage depth across 353 exons
targeted by amplicons in this assay. B: Coverage (y axis) versus GC content
for all targeted exons. CEBPA appears in red.
Deep Sequencing of Microdroplet PCR<amplicon interval list file> -rf Fail-
sVendorQualityCheck -rf NotPrimaryAlignment -
rf MappingQualityUnavailable -rf UnmappedRead
7) SomaticIndelDetector: paired-sample mode
java -Xmx4g -jar GenomeAnalysisTK-2.2-8/
GenomeAnalysisTK.jar -T SomaticIndelDetector
--maxNumberOfReads 100000 -I:tumor <Tumor bam
file> -I:normal <Normal bam file> -filter
y’T_COV<10jjT_INDEL_F<0.0001jjT_INDEL_CF<0.7-
y’ -verbose <verbose output> -o <standard out-
put> -metrics <metrics file> -R <hg19 genome
referencefasta> -L<ampliconintervallistfile>
-rf FailsVendorQualityCheck -rf NotPrimar-
yAlignment -rf MappingQualityUnavailable -rf
UnmappedRead
8) Annovar
perl<annovar folder>/annotate_variation.pl
-geneanno <annovar input file> -buildver hg19
<annovar folder>/humandb
Results
Overview of Coverage across Sequenced Samples
We designed a custom panel with 847 amplicons with the
RainDance DeepSeq platform, targeting 353 exons across
28 genes known to be involved in pathogenesis of myeloid
malignancies. Sixty-six replicates corresponding to 30
samples with known mutations in JAK2, NPM1, FLT3,
MPL, DNMT3A, IDH1, and IDH2 were subjected to
microdroplet-PCR using the RainDance Thunderstorm
system, followed by sequencing on an Illumina MiSeq. The
amplicons were sequenced to a mean (SD) depth of 1765
(756), whereas mean (SD) coverage within the 353 tar-
geted exons was high at 2011 (765) (Table 1 and
Figure 1A). Amplicon length ranged from 127 to 155 bp in
length, and most targeted exons [276 of 353 (78%)] were
tiled by more than 1 amplicon (Supplemental Tables S3 and
S4 and Supplemental Figure S1). Targeted exons were tiled
densely by overlapping amplicons (amplicon area/targeted
area Z 1.5) to achieve bidirectional coverage of most of
the targeted area (97%). Coverage for some exons with high
GC content was lower than average (ie, CEBPA exon 1,
FLT3 exon 1, and SH2B3 exon 2), but in general no asso-
ciation was found between target region GC content andTable 1 Comparison of Regions Covered by Amplicon Assay
Covered region
Area
(kbp)
Mean (SD)
coverage
COSMIC coding
variants
Tiled by amplicons 94.6 1765 (673) 752
Targeted exons 64.6 2011 (765) 752
Targeted exons with
bidirectional coverage
62.9 2021 (767) 740
COSMIC, Catalogue of Somatic Mutations in Cancer.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgcoverage (Figure 1B). A listing of all targeted exons, their
GC content, mean coverage, and amplicon tiling density can
be found in Supplemental Table S4. A survey of coding
mutations with at least ﬁve mentions in COSMIC version 64
revealed that our assay was capable of interrogating 740
known variants in the targeted regions with bidirectional
coverage. These mutations include well-characterized hot-
spots, such as JAK2 V617F and NPM1 exon 11 insertions,
as well as point mutations at KRAS G12, IDH1 R132, and
NRAS Q61. Most targeted exons (97%) were sequenced to a
depth >500 (Table 2), with the exception of 12 exons
listed in Supplemental Table S5. Six exons failed to present
with any sequence coverage at all. These exons contain only
one COSMIC variant (PTEN F347fs, six mentions), so their507
Cheng et allack of coverage should have minimal effect on the ability
of the assay to interrogate known mutations. To determine
whether poor coverage of these exons was due to bad
amplicon design, we performed PCR followed by Sanger
sequencing for nine of these low-coverage exons using the
same amplicon primers as the RainDance assay. Twelve
amplicons were tested in total (Supplemental Table S6). A
clear PCR product was obtained for 11 of the 12 amplicons,
but Sanger sequencing revealed that the PCR product
matched the expected sequence in only 8 of 11 cases, sug-
gesting the lack of coverage for these regions may indeed be
due to primer design issues.
Comparison of Single- versus Paired-Sample Analysis
Because many of the commonly used variant calling algo-
rithms require matched samples for analysis, we sought to
investigate the effect of using a Hapmap DNA sample as an
unmatched normal control for paired-sample variant calling
(paired-sample analysis) versus performing variant calling on
the tumor sample alone (single-sample analysis). Three
classes of variants were considered: point mutations and
SNVs, short insertions and deletions or indels (<25 bp), and
medium-sized ITDs (25 to 100 bp). Variant calling for SNVs
and indels was performed using two independent algorithmsTable 2 List of Exons Covered per Gene in Panel and Corresponding C
Gene Refseq
No. of
amplicons
Exons
covered
Cod
exo
MPL NM_005373 1 10 1e
JAK1 NM_002227 47 2e25 2e
NRAS NM_002524 6 2e4 2e
DNMT3A NM_022552 37 2e23 2e
SF3B1 NM_012433 55 1e25 1e
IDH1 NM_005896 16 3e10 3e
KIT NM_000222 41 1e21 1e
TET2 NM_001127208 62 3e11 3e
NPM1 NM_002520 1 11 1e
EZH2 NM_004456 31 2e20 2e
JAK2 NM_004972 51 3e25 3e
TET1 NM_030625 69 2e12 2e
PTEN NM_000314 18 1e9 1e
WT1 NM_024426 20 1e10 1e
CBL NM_005188 36 1e16 1e
ETV6 NM_001987 18 2e8 1e
KRAS NM_033360 8 2e4 2e
SH2B3 NM_005475 23 2e8 2e
FLT3 NM_004119 44 1e24 1e
IDH2 NM_002168 23 1e11 1e
TP53 NM_000546 16 2e11 2e
SUZ12 NM_015355 30 1e16 1e
TYK2 NM_003331 47 3e25 3e
JAK3 NM_000215 50 2e23 2e
CEBPA NM_004364 12 1 1
ASXL1 NM_015338 57 1e12 1e
RUNX1 NM_001754 16 4e9 2e
PHF6 NM_032458 16 2e10 2e
508to verify that the difference observed in single versus paired
analysis was not algorithm speciﬁc. In addition, the algo-
rithms used were deliberately chosen based on their ability to
be run in both single-sample and paired modes.
Regardless of algorithm used, both single and paired-
sample pipelines were able to detect the known variant
associated with each sample in all cases, using baseline
ﬁlters of 100 coverage depth and 1% variant frequency.
Summary statistics for each known variant are reported in
Table 3. Although the known variants were detected in re-
gions of deep coverage, exceeding 1000 in most cases, the
number of mutant reads and the variant frequency varied,
depending on the type of mutation. The JAK2 V617F mu-
tation was detected at high frequencies (23% to 78%),
whereas the FLT3 ITD was detected at lower frequencies
(0.6% to 15%).
Use of an unmatched normal control in paired analysis
resulted in fewer variants being called overall (Figure 2,
Supplemental Tables S7 and S8). For SNVs, running
MuTect in paired analysis reduced the number of calls from
371 to 184 (approximately 50%), whereas calls made with
VarScan2 were reduced from 2533 to 1630 (approximately
36%). Similarly, for indels, running SomaticIndelDetector
in paired analysis reduced the number of calls from 309
to 125 (approximately 59%), whereas calls made withoverage Summary
ing
ns
Mean coverage
across exons
Lowest
covered exon
Highest
covered exon
12 1887.3 1887.3 1887.3
25 2167.6 654.2 4802.3
5 2182 1338.7 2667.7
23 1946.9 0 4196
25 1683.8 535.4 2688.2
10 2118.6 1227.8 3410.2
21 2080.2 901.9 4449
11 2154.9 1213.8 3387.7
11 2055.1 2055.1 2055.1
20 1698 0 2733.3
25 1978.2 393.3 4172.6
12 2296.5 1253.1 4297.8
9 1453.7 225.9 2595.1
10 1844.9 0 3058.7
16 2473.8 1335.9 3287.8
8 2080.2 1211.1 3057.8
5 2143.3 1308.8 2610.9
8 2246.2 1417.4 2967.2
24 2087.5 1103.9 3989.9
11 2248.8 1404.6 3239
11 1946.8 387.1 3150.1
16 1415.4 0.1 2906.1
25 2147.9 649 4122
24 2472.6 723.7 3606.8
1512.3 1512.3 1512.3
12 2027.9 541 3078.6
9 2440.9 1740.2 3554.8
10 1152.6 409.3 1738.3
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Table 3 Median (Range) Coverage, Number of Mutant Reads, and Variant Frequency Reported for Each Known Variant Detected
Known variant No. of amplicons Coverage No. of mutant reads Variant frequency
NPM1 W288 fs 34 1643 (457e3438) 324 (34e764) 0.22 (0.02e0.30)
FLT3 ITD 30 1707.5 (598e5685) 49.5 (8e375) 0.029 (0.006e0.15)
JAK2 V617F 27 2550 (973e3928) 1163 (340e2883) 0.46 (0.32e0.83)
DNMT3A R882 3 3510 (3363e3971) 1214 (988e1680) 0.36 (0.25e0.48)
CEBPA1 A358_*359insSG 1 3790 (3790e3790) 1254 (1254e1254) 0.33 (0.33e0.33)
CEBPA A211P 1 1017 (1017e1017) 246 (246e246) 0.24 (0.24e0.24)
IDH1 R132S 1 2143 (2143e2143) 665 (665e665) 0.31 (0.31e0.31)
IDH2 R140Q 1 2998 (2998e2998) 1045 (1045e1045) 0.35 (0.35e0.35)
MPL W515L 1 2482 (2482e2482) 2377 (2377e2377) 0.96 (0.96e0.96)
SNVs
MuTect VarScan2
Indels
SomacIndelDetector (SOM) VarScan2
187
184
903
1630
7
184
125
216
84
Figure 2 Comparison of single nucleotide variants (SNVs) and indel
calls made in single (white circles) versus paired (gray circles) sample
analysis by MuTect, VarScan2, and SomaticIndelDetector. Algorithms were
deliberately chosen because they could be run in both single and paired
modes.
Deep Sequencing of Microdroplet PCRVarScan2 were reduced from 300 to 84 (approximately
72%). Comparison of ITD calls between single and paired
analysis modes was not possible because Pindel does not
support paired sample analysis. Instead, ITD calling was
performing on tumor and Hapmap samples separately, and
tumor calls were ﬁltered for calls common to both tumor
and Hapmap samples. There were 84 ITD calls before and
after ﬁltering because no ITDs were found to be common
between tumor and Hapmap samples.
In general, calls made in paired analysis were a subset of the
original set of calls made in single-sample analysis, suggesting
that comparison against a Hapmap control acted as a ﬁlter,
removing low-conﬁdence variants without introducing addi-
tional calls. SNVs detected using VarScan2 were the only
exception; seven new calls were made in paired analysis that
had not been previously detected in single-sample mode. On
further inspection, we determined that these variants were
borderline calls that barely passed the criteria for being called;
despite being in a region of high coverage (approximately
500), all seven had <10 reads supporting the mutant allele
and were detected at variant frequencies close to 1%.
Characterization of Calls Filtered Out by Paired-Sample
Analysis
We hypothesized that the variant calls ﬁltered out by paired-
sample analysis were likely nonspeciﬁc amplicon-
sequencing related artifacts, which would recur in multiple
unrelated samples. To test this hypothesis, we divided the
variant calls into two groups (ie, calls unique to single-
sample analysis and calls made by paired-sample analysis)
and examined their recurrence across samples that had been
assayed without replicates.
Although calls unique to single-sample analysis out-
numbered those made in paired mode, they often consisted of
multiple calls of the same variant that recurred across several
samples (Figure 3; Supplemental Figure S2 shows an
example of a SNV that was called by single-sample analysis
only and was recurrent in all 12 samples: JAK2 I955L). There
were fewer unique variants among calls made by single-
sample analysis only compared with calls made in paired
analysis. Most calls made by paired analysis were only called
once and were speciﬁc to the tumor they were detected in. InThe Journal of Molecular Diagnostics - jmd.amjpathol.orggeneral, this was observed for both SNVs and indels,
regardless of the algorithm used for variant calling.
Furthermore, calls unique to single-sample analysis tended to
be supported by fewer reads that contained the mutant allele
and generally had variant frequency values of approximately
2% to 4% (Figure 4 and Supplemental Table S9). In contrast,
calls made in paired analysis were supported by more mutant
reads and had robust variant frequencies of approximately
20% for SNVs (MuTect) and 10% for indels (Somati-
cIndelDetector and VarScan2). VarScan2 called almost 10
times as many SNVs as MuTect, even in paired analysis.
Most of these additional calls had low variant frequencies,
indicating that VarScan2 may be more permissive than
MuTect when operating in paired-analysis mode.
As independent veriﬁcation, we performed Sanger
sequencing on samples positive for variants called by single-
sample analysis and not paired-sample analysis to determine
whether these variants were indeed false positives. A total of
10 SNVs and 8 indels were chosen for conﬁrmation; where
possible, we used in Sanger sequencing for the same set of
amplicon primers from the RainDance panel. Multiple509
Figure 3 Calls made in single-sample mode but not in paired mode (red)
are compared against calls made in both single and paired analysis modes
(green) in terms of their recurrence among unrelated samples from different
individuals. Calls made in single-sample mode but not in paired mode
correspond to repeated calls of a smaller subset of variants that are highly
recurrent and are likely to be artifacts. SNV, single nucleotide variant.
Figure 4 Comparison of coverage depth and variant frequency between
calls made in single-sample mode alone and calls made in both single- and
paired-sample modes. SNV, single nucleotide variant.
Cheng et alsamples were Sanger sequenced for the same variant, if the
variant was recurrently called across samples (Supplemental
Table S10). None of the variants were present in any of the
tested samples by Sanger sequencing, supporting the hy-
pothesis that calls made in single-sample analysis only were
indeed assay artifacts and false positives.
Reproducibility of Paired-Analysis Calls
Having determined that the calls unique to single-sample
analysis were likely artifacts, we sought to compare the
performance of the algorithms in terms of reproducibility of
paired-analysis calls across intrarun and interrun replicates
of a given sample. We ﬁrst examined the reproducibility of
calls corresponding to the known variants. Where possible,
different barcodes were chosen for the interrun replicates to
minimize demultiplexing-related effects. As expected, all
algorithms successfully detected the known variants across
intrarun and interrun replicates with similar variant fre-
quencies and coverage values (Tables 4 and 5).
Next, we combined intrarun and interrun replicates for a
given sample and asked how the algorithms compared in
terms of general reproducibility of calls across all replicates.
For SNVs, 107 of the 184 calls from MuTect were made on
the subset of samples with replicates, and of these, 50 calls
(47%) were reproducible across all replicates (Table 6). In
contrast, 1143 of 1630 calls from VarScan2 were made on
the same subset of samples, but only 5% of them were
reproducible. All 50 reproducible MuTect calls were also
called and conﬁrmed reproducible by VarScan2. There were510eight additional reproducible calls made by VarScan2 that
were not conﬁrmed as reproducible by MuTect; these cor-
responded to repeated calls of a missense mutation in
SUZ12 (S249L) that was made across eight replicates of
sample M_1101_1. On closer inspection, we determined
that MuTect did make the call in ﬁve of the eight replicates
but rejected the variant in the remaining replicates, citing
strand bias and contamination as reasons for rejection.
For indels, both SomaticIndelDetector and VarScan2 re-
ported an identical set of 32 calls as reproducible across all
replicates. Interestingly, a larger percentage of VarScan2
indel calls were reproducible compared with Somati-
cIndelDetector (53% versus 36%), suggesting VarScan2 may
be more selective at making indel calls in paired-analysis
mode than SomaticIndelDetector. This is noteworthy, espe-
cially because VarScan2 does not appear to be as selective in
making reproducible SNV calls. For ITDs, 24 of 65 Pindel
calls (37%) were reproducible across replicates. We noted
that all 24 calls corresponded to known variants; no other
new variants were reproducible.
Comparing characteristics of reproducible versus non-
reproducible calls, we observed that in general, reproduciblejmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 4 Intrarun Reproducibility for Known Variant Associated with Each Sample
Sample Known variant Run Barcode Mean coverage Variant frequency Normalized coverage
M_1101_01 JAK2 V617F 3 bc06 2902 0.324 1.09
bc07 2258 0.43 0.88
bc08 2550 0.454 0.91
M_1101_01-2 JAK2 V617F 7 bc05 2989 0.377 0.93
bc06 2570 0.428 1
bc07 2643 0.397 0.83
bc08 3059 0.469 0.94
M_1143_55 JAK2 V617F 6 bc01 1332 0.509 0.71
bc02 2463 0.479 0.88
bc03 2361 0.359 1.05
bc04 2510 0.463 0.84
M_1147_E3 JAK2 V617F 6 bc05 2344 0.789 0.85
bc06 2701 0.749 0.91
bc07 2411 0.756 0.86
bc08 3258 0.79 0.94
M_1170_D1 NPM1 W288fs 8 bc01 2242 0.136 0.83
bc02 2268 0.144 0.85
bc03 1624 0.137 0.75
M_1478_D8 NPM1 W288fs 3 bc01 1598 0.22 0.68
bc02 1541 0.259 0.6
bc03 1662 0.221 0.73
M_1485_FC NPM1 W288fs 4 bc02 532 0.246 0.53
bc03 528 0.199 0.67
bc04 875 0.191 0.62
M_1485_FC-2 NPM1 W288fs 7 bc01 1588 0.217 0.73
bc02 1681 0.265 0.74
bc03 1575 0.301 0.74
bc04 1510 0.216 0.71
M_1487_3F NPM1 W288fs 5 bc02 1208 0.273 0.7
bc03 750 0.265 0.78
bc04 907 0.245 0.72
bc05 734 0.238 0.64
M_1170_D1 FLT3_ITD_84bp 8 bc01 1450 0.026 0.54
bc02 1912 0.026 0.72
bc03 1487 0.02 0.69
M_1478_D8 FLT3_ITD_93bp 3 bc01 3264 0.014 1.38
bc02 3323 0.017 1.3
bc03 3300 0.021 1.44
M_1485_FC FLT3_ITD_18bp 4 bc02 998 0.097 0.99
bc03 678 0.115 0.86
bc04 1226 0.086 0.87
M_1485_FC-2 FLT3_ITD_18bp 7 bc01 1415 0.151 0.65
bc02 1821 0.146 0.8
bc03 1645 0.142 0.77
bc04 1730 0.149 0.81
M_1487_3F FLT3_ITD_57bp 5 bc02 2471 0.007 1.44
bc03 1339 0.008 1.39
bc04 1719 0.008 1.37
bc05 1858 0.006 1.63
Deep Sequencing of Microdroplet PCRcalls were supported by greater numbers of mutant reads
and tended to have higher variant frequencies than non-
reproducible calls (P < 0.05, Welch’s t-test). There was no
association with coverage depth and reproducibility of calls
across replicates. Interestingly, with the exception of ITD
calls, we were able to separate calls into reproducible versus
nonreproducible groups by ordering calls in terms of variantThe Journal of Molecular Diagnostics - jmd.amjpathol.orgfrequency (Figure 5). For instance, all calls detected by
MuTect with variant frequency >15% were reproducible,
and all calls below this cutoff for variant frequency were
uniformly nonreproducible. Similarly, almost all indel calls
>5% variant frequency (32 of 35) for both Somati-
cIndelDetector and VarScan2 were reproducible. The three
nonreproducible calls above this cutoff corresponded to a511
Table 5 Interrun Reproducibility for Known Variant Associated with Each Sample
Sample Known variant Run Barcode Mean coverage Variant frequency Normalized coverage
M_1101_01 JAK2 V617F 3 bc06 2902 0.324 1.09
4 bc05 1224 0.529 0.99
7 bc07 2643 0.397 0.83
M_1108_35 JAK2 V617F 3 bc09 2389 0.535 0.9
5 bc07 1149 0.486 0.95
7 bc09 2850 0.492 1.1
M_1482_E1 JAK2 V617F 2 bc07 3240 0.374 0.82
4 bc08 973 0.349 0.79
5 bc08 1169 0.334 0.87
M_1478_D8 NPM1 W288fs 2 bc03 2384 0.266 0.75
3 bc02 1541 0.259 0.6
4 bc01 589 0.244 0.62
M_1483_89 NPM1 W288fs 2 bc08 2702 0.198 0.76
4 bc09 436 0.119 0.61
5 bc09 621 0.229 0.55
11 bc07 1504 0.249 0.72
M_1485_FC NPM1 W288fs 4 bc02 532 0.246 0.53
5 bc01 692 0.195 0.62
7 bc03 1575 0.301 0.74
M_1478_D8 FLT3_ITD_93bp 2 bc03 4240 0.048 1.33
3 bc02 3323 0.017 1.3
4 bc01 1174 0.021 1.24
M_1483_89 FLT3_ITD_42bp 2 bc08 1654 0.137 0.79
4 bc09 2611 0.144 0.74
5 bc09 597 0.084 0.83
11 bc07 833 0.044 0.73
M_1485_FC FLT3_ITD_18bp 4 bc02 998 0.097 0.99
5 bc01 749 0.031 0.68
7 bc03 1645 0.142 0.77
Cheng et alWT1 exon 7 insertion (R369fs) that was not considered
reproducible because it had failed a test for possible strand
bias in one of the four replicates.
Interestingly, a substantial number of SNV calls below the
15% cutoff were not reproducible because they were detected
in one replicate but completely absent in the other replicates
(ie, singleton calls). For instance, MuTect called the SUZ12
I528T variant with frequency 13.6% in only one replicate of
M_1101_01; no other reads supporting this variant could be
found in other replicates, even by genotyping. These
singleton calls likely arose from random mismatch errors
introduced in repeated cycles of PCR ampliﬁcation; being
random in nature, these artifacts would not occur at the same
position in a different sample and thus would not be ﬁltered
out in paired-sample analysis. Furthermore, the occurrence of
singleton calls across replicates appeared to be speciﬁc to
SNVs; a comparison of indel calls across replicates did not
reveal any obvious singleton calls. This ﬁnding could reﬂect
a tendency for polymerase-related errors in PCR to result in
random base substitutions and mismatches, as opposed to
introduction of random indels.
Again, Sanger sequencing was performed on samples pos-
itive for 9 reproducible and 20 nonreproducible variant calls to
determine the extent to which nonreproducible, singleton calls
were false positives (Supplemental Table S11). All 9512reproducible variant calls were conﬁrmed to be present, but
none of the 20 nonreproducible calls could be conﬁrmed.
Some of the nonreproducible singleton SNV calls had been
detected with variant frequencies as high as 6% to 7%, which
was almost as high as some true-positive reproducible calls
(mean variant frequency of SUZ12 S249L in positive
samples of 9.1%). These results suggest that call reproduc-
ibility may be a good predictor of true-positive results and
could be used as a surrogate measure in cases where inde-
pendent conﬁrmation by Sanger sequencing is unavailable.
Test of Analytic Sensitivity Using a Dilution Series
As a test of analytic sensitivity, DNA from two tumor
samples positive for JAK2 V617F and NPM1 W288fs were
serially diluted into Hapmap control DNA and subjected to
proﬁling by the assay. Variants were called at each dilution
level by different algorithms run in paired-analysis mode.
Results for MuTect for SNVs and SomaticIndelDetector for
Indels are presented in Table 7. Both the JAK2 point mu-
tation and NPM1 insertion failed to be detected reliably after
the 3.12% dilution level. Assuming the variant frequencies
in the undiluted sample accurately reﬂect the true underlying
frequency, this would suggest that the analytic sensitivity of
the assay for the assay is approximately 1.4% for SNVsjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 6 Characteristics of Reproducible and Nonreproducible Variants Called in Replicate Samples
Variant Method Parameter Reproducible calls Nonreproducible calls P
SNV MuTect N 50 (0.47) 57 (0.53)
DP 2607 (2284e2930) 2913 (2533e3293) 0.22
AD 1227 (978e1476) 146 (106e186) <0.001
VF 0.469 (0.422e0.516) 0.049 (0.040e0.058) <0.001
VarScan2 N 58 (0.05) 1085 (0.95)
DP 2475 (2181e2769) 2153 (2066e2240) 0.04
AD 1080 (845e1315) 33 (30e36) <0.001
VF 0.417 (0.364e0.470) 0.015 (0.014e0.016) <0.001
Indel SomaticIndelDetector N 32 (0.36) 56 (0.64)
DP 1243 (1023e1463) 1522 (1183e1861) 0.17
AD 320 (263e377) 41 (16e66) <0.001
VF 0.268 (0.233e0.303) 0.026 (0.013e0.039) <0.001
VarScan2 N 32 (0.53) 28 (0.47)
DP 1244 (1024e1464) 1735 (1320e2150) 0.04
AD 320 (263e377) 66 (16e116) <0.001
VF 0.268 (0.233e0.303) 0.040 (0.014e0.066) <0.001
ITD Pindel N 24 (0.37) 41 (0.63)
DP 1812 (1413e2211) 1181 (970e1392) 0.007
AD 105 (61e149) 12 (10e14) <0.001
VF 0.064 (0.040e0.088) 0.014 (0.011e0.017) <0.001
Number of calls (N), coverage depth (DP), number of mutant reads (AD), and variant frequencies (VF) are represented as means (95% CI). Differences
between reproducible and nonreproducible calls are evaluated for signiﬁcance using Welch’s t-test.
Deep Sequencing of Microdroplet PCR(0.0312  43.2%Z 1.37%) and 0.9% for Indels (0.0312 
27.8%Z 0.9%). This is consistent with a baseline ﬁlter for
100 coverage and 1% variant frequency imposed on all
raw variant calls.
Similar to potential false-positive results observed in the
reproducibility analysis, we observed a number of variants
that were not detected in the undiluted sample but were
subsequently called in one of the lower dilution levels. Not
only were these calls undetected in the undiluted sample,
but they also did not show a consistent trend of decreasing
variant frequency with subsequent dilutions as exempliﬁed
by the known variant (Figure 6), suggesting they may be
false-positive results. Compared with 12 SNVs and 3 indels
called on the undiluted sample, 35 SNVs and 15 indels were
called in at least one of the six lower dilution levels and
absent in the undiluted sample. The variant frequencies for
these potential false-positive results can be as high as 17%
for SNVs and 5.7% for indels but are mostly <15% and 5%,
the thresholds for SNVs and indels identiﬁed in the repro-
ducibility analysis.
Filtering for High-Conﬁdence Variants
The reproducibility and dilution series experiments sug-
gest that although the assay is capable of detecting low-
frequency variants, doing so may come at the cost of
incurring random false-positive results with variant fre-
quencies that occasionally are in range of some true-
positive results. Using call reproducibility as a proxy for
speciﬁcity, we computed receiver operating characteristic
curves to determine the extent to which cutoffs on variantThe Journal of Molecular Diagnostics - jmd.amjpathol.orgfrequency can be used to predict reproducibility for each
variant class (ie, SNVs, indels, and ITDs). An area under
the curve (AUC) value of 1 indicates that a cutoff on
variant frequency can perfectly classify calls as repro-
ducible versus nonreproducible. The results of the receiver
operating characteristic analysis are shown in Figure 7.
MuTect and SomaticIndelDetector had higher AUC values
than VarScan for SNV and indel calling, respectively,
whereas the AUC value for Pindel was markedly lower
(approximately 0.8).
On the basis of these AUC values, MuTect and Soma-
ticIndelDetector were selected as default algorithms for the
paired-sample analysis pipeline. We considered mutations
with variant frequencies >15% for SNVs and 5% for
indels as high-conﬁdence mutations. Because reproduc-
ibility of ITD calls could not be determined based on
variant frequency alone, we pursued a candidate geno-
typing strategy where Pindel was used to call ITDs only in
exon 14 of FLT3. By this criterion, 75 SNVs and 48 indel
calls were considered high conﬁdence and hence likely
reproducible (Supplemental Tables S12 and S13). These
high-conﬁdence calls included all calls corresponding to
known variants, as well as other high well-characterized
hotspot mutations in hematologic cancers, such as FLT3
D835H,32 indels in WT1,33,34 and TET2 Q916.35 Sanger
sequencing conﬁrmed a number of these mutations to be
present in the samples they had been detected in (ie, TET2
Q916 and WT1 R369fs; Supplemental Table S11). Taken
together, these data suggest our assay may be identifying
bona ﬁde mutations not previously detected by other
methods.513
Figure 5 Distribution of variant frequencies for single nucleotide variant (SNV) (A), indel (B), and internal tandem duplication (IDT) (C) calls made by
MuTect, VarScan2, SomaticIndelDetector (SOM), and Pindel on samples assayed in triplicate or greater. Calls corresponding to reproducible variants (red),
nonreproducible variants (gray), known variants in these samples (triangles), variants not previously identiﬁed (circles), and a variant frequency of 15% for
SNV calls or 5% for indel calls (dashed line) are shown.
Cheng et alDiscussion
In this study, we developed a 28-gene custom amplicon
panel for use with the RainDance microdroplet-PCR and
the Illumina MiSeq system to identify commonly recurrentTable 7 Coverage and Variant Frequencies for Known Variants at Vari
Sample Known variant Dilution (%) Mean coverag
M_1108_35 JAK2 V617F 100 1580
50 1797
25 1187
12.50 3795
6.25 1629
3.12 2074
1.56 1958
M_1478_D8 NPM1 W288 fs 100 1619
50 2325
25 2581
12.50 1862
6.25 3210
3.12 2400
1.56 2918
Called indicates that the variant was detected by the respective algorithm used
Detector). In cases where the known variant was not called, genotyping was perform
*This variant call had passed the 100 coverage and 1% variant frequency b
contamination.
514mutations in myeloid malignancies. The assay was designed
to interrogate 353 exons within this gene set and achieved
high coverage on average (approximately 2000) across
most targeted exons, with only 12 exons with <500 mean
coverage. Although the high-sequencing coverage depthous Dilution Levels
e Variant frequency Normalized coverage Called
0.432 0.8 Yes
0.221 1.03 Yes
0.153 0.94 Yes
0.048 1.27 Yes
0.037 0.9 Yes
0.027 0.99 No*
0.001 1.01 No
0.278 0.64 Yes
0.152 0.95 Yes
0.061 0.95 Yes
0.052 1 Yes
0.011 1.21 Yes
0.009 1.08 No
0.014 1.17 Yes
for single nucleotide variation and indel calling (MuTect and SomaticIndel
ed to obtain coverage and variant frequencies at the location of the mutation.
aseline ﬁlter but was rejected by a statistical ﬁlter in MuTect for possible
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 6 A: Variant frequencies of single
nucleotide variation (SNV) and indel calls made by
MuTect and SomaticIndelDetector on the undiluted
sample, tracked across successive serial dilutions.
Known variant associated with sample is shown in
red. B: Variant frequencies of SNV and indel calls
that were not called on the undiluted sample but
called at lower dilution levels.
Deep Sequencing of Microdroplet PCRenables discovery of bona ﬁde low-frequency variants, ar-
tifacts introduced in repeated cycles of PCR ampliﬁcation
and sequencing may also be detected as variants, elevating
the false-positive rate. As a solution in most solid-tumor
proﬁling studies, tumors are frequently assayed along with a
normal sample from the same patient (blood or normal
tissue adjacent to the tumor site), and variant calling is
performed on tumorenormal control pairs to ensure only
somatic mutation events are detected.
Unlike solid tumor testing, blood samples cannot be
used as a comparator normal control for hematologic
cancers because cancer cells are borne in the blood itself.
Because other matched normal control alternatives for
blood are frequently unavailable in routine diagnosticFigure 7 Receiver operating curves for single nucleotide variation (SNV), indel, an
sample analysis [MuTect, SomaticIndelDetector (SOM), Varscan2 and Pindel]. Varian
replicates; an areaunder the curve (AUC) value close to1 indicates a cutoffon variant fre
The dashed line indicates an AUC value of 0.5, the case where the parameter being ev
The Journal of Molecular Diagnostics - jmd.amjpathol.orgtesting, we investigated the use of a generic Hapmap cell
line as an unmatched normal control for paired-sample
analysis. Both single-sample and paired-sample analysis
pipelines succeeded in retrieving the known variant asso-
ciated with the samples tested, but the comparison versus
the Hapmap control in paired analysis behaved like a ﬁlter
and reduced the overall number of calls without intro-
ducing any additional calls (exception: VarScan2 for
SNVs). The calls ﬁltered out in paired-sample analysis
tended to be nonunique and recurrent across multiple un-
related samples. These calls were also supported by fewer
mutant reads and had lower variant frequencies, providing
further evidence that these calls were indeed artifacts. We
performed Sanger sequencing on 18 variant calls unique tod internal tandem duplication (ITD) calls detected by variousmethods in paired-
t frequency was evaluated as a predictor of call reproducibility across sample
quency canclearly discriminate between reproducible andnonreproducible calls.
aluated is no more predictive than a random 50-50 coin toss.
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Cheng et alsingle-sample analysis and found them to be false-positive
results in every sample they were tested in.
The observation that a large number of single-sample
calls are removed by comparing against an unmatched
control sample suggests that for the RainDance DeepSeq
platform artifacts are incorporated at stereotypic locations
and at sites common to both tumor and normal control
samples. This feature may be unique to the DeepSeq
microdroplet-PCR protocol and may not be true in general
for other amplicon sequencing platforms, such as the Illu-
mina TruSeq Amplicon assay or the IonTorrent AmpliSeq
system. Paired-sample analysis using an unmatched normal
control sample may be of limited utility in multiplexed PCR
platforms where artifact calls that result from polymerase
errors occur at random locations and are not reproducible
across samples.
In comparing paired-sample variant calls across replicates,
we observed that variant frequency was a strong predictor of
call reproducibility for SNVs and indels. Because samples
are unlikely to be run in replicate during routine clinical
testing, the results of the reproducibility analysis help inform
the choice of variant frequency cutoff for high-conﬁdence
mutations. Variants with frequencies >15% for SNVs and
5% for indels were more likely to be reproducible. This was
further reinforced by dilution series experiments, in which
likely false-positive results (variants not detected in the un-
diluted sample but called in lower dilutions) were detected
with variant frequencies lower than these cutoff values. In
clinical practice, a cutoff value of 15% for SNVs may be too
conservative and may result in bona ﬁde, low-frequency
mutations in hotspot locations being missed for the sake of
rejecting all false-positive results. Assuming manual review
of variant calls will be performed after ﬁltering in clinical
practice, a lower cutoff value for SNVs could be used (ie,
5%). This would come with the understanding that SNVs in
the 5% to 15% frequency range should be examined with
heightened scrutiny, especially if they correspond to clini-
cally actionable mutations.
ITD calls in FLT3 identiﬁed using Pindel had lower
variant frequencies in general, and unlike SNVs and indels,
reproducibility of these calls could not be clearly predicted
by their variant frequency. The calls we identiﬁed as cor-
responding to known FLT3 ITD variants range in length
from 18 to 93 bp; given their size, these events may disrupt
primer annealing and cause amplicons overlapping the ITD
to be ampliﬁed poorly. This could explain the relatively
lower variant frequencies observed for ITDs compared
with other indels of shorter length. This would also argue
for the need to extensively tile regions where ITDs
frequently occur with a higher density of overlapping
amplicons.
In a recent study, Spencer et al36 were able to use
Pindel and de novo assembly methods to identify ITDs in
FLT3 in all specimens previously conﬁrmed to be ITD
positive by PCR and capillary electrophoresis. Despite
having similar levels of coverage for FLT3 exon 14516(>2000 in both cases), the ITDs reported by Pindel in
the study by Spencer et al36 had higher variant fre-
quencies (mean, 21.8%) than observed in our study
(mean, 2.9%). This ﬁnding could be due to differences in
enrichment protocol (hybridization capture versus
amplicon PCR); multiple, independent captures of the
FLT3 ITD locus may have allowed more accurate esti-
mates of the true variant frequency of the ITD event
compared with ﬁve amplicons tiling exons 13 to 15 of
FLT3 in our assay. The authors also found that Pindel-
reported ITD variant frequencies are not precise esti-
mates of actual variant frequency values compared with
values derived from PCR-capillary electrophoresis, and
estimates of ITD frequencies are clearly less precise
using an amplicon assay. Taken together, these results
suggest that FLT3 ITD events identiﬁed by Pindel on
RainDance amplicon data should be conﬁrmed by an
independent method before being reported. This would
be consistent with current status quo given the Takara
Bio/Invivoscribe (San Diego, CA) patent on FLT3 ITD
testing but may change in the future in light of the US
Supreme Court decision on Association of Molecular
Pathology v. Myriad Genetics and as more precise bio-
informatics approaches for estimating ITD variant fre-
quencies from NGS data are developed.
In summary, our results indicate that variant calling
using an unmatched normal control removes a substantial
number of artifactual calls that recur in a nonspeciﬁc
fashion across multiple unrelated samples. These ﬁndings
provide a case for including a generic Hapmap control
sample for paired-sample analysis in routine NGS clinical
diagnostic testing. On the basis of results of the repro-
ducibility analysis, we established cutoffs on variant fre-
quency that are predictive of call reproducibility and we
assume, by extension, true-positive calls. This assumption
may be too conservative because it risks ﬁltering out real
low-frequency mutations for the sake of rejecting all po-
tential false-positive results. Cutoffs of 5% on variant
frequency for both SNVs and indels may be more appro-
priate in a clinical setting, with the understanding that
SNVs with variant frequencies between 5% and 15%
should be reviewed with increased scrutiny and possibly
even conﬁrmed by repeating the sample in a subsequent
run, especially if the low-frequency mutation call corre-
sponds to an actionable event. FLT3 ITDs can be detected
on RainDance data using Pindel, but reported variant fre-
quencies are likely underestimates, and these events should
be conﬁrmed by an independent method before being re-
ported. With the use of conservative thresholds, the ﬁnal
paired analysis pipeline called a total of 154 high-
conﬁdence variants (75 SNVs, 48 indels, and 31 ITDs)
across 66 samples or a mean of 3 calls per sample. These
ﬁndings provide proof-of-concept that a custom amplicon
panel based on the RainDance DeepSeq platform can be
used to identify mutations in myeloid malignancies in a
clinical diagnostic test.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Deep Sequencing of Microdroplet PCRSupplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.jmoldx.2014.05.006.
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